In the last 12 months, insiders at FATE THERAPEUTICS INC ($FATE) filed 118 transactions with the SEC: 7 open-market purchases totaling $3,392,771 and 32 sales totaling $3,268,182. Net insider sentiment: net buying.
FATE THERAPEUTICS INC operates in the Biological products, (no disgnostic substances) industry (Life sciences sector).
Most Active Insiders
- Redmile Group, LLC (Director) — 30 transactions totaling $89,771,762
- MENDLEIN JOHN (Director) — 5 transactions totaling $737,130
- Wolchko J Scott (President and CEO) — 4 transactions totaling $303,441
- TAHL CINDY (General Counsel and Secretary) — 6 transactions totaling $166,528
- Dulac Edward J III (Chief Financial Officer) — 10 transactions totaling $160,138
View all SEC Filings for FATE THERAPEUTICS INC (FATE).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 15, 2026 | Adawi Kamal | Chief Financial Officer | A | Common Stock | 25000 | $0.00 | 100,000.0000 | 118,998,693 | 33.33% | 0.02% |
| Jan. 15, 2026 | TAHL CINDY | See Remarks | A | Stock Option (Right to Buy) | 400000 | $0.00 | 400,000.0000 | 118,998,693 | 9999.99% | 0.34% |
| Jan. 15, 2026 | TAHL CINDY | See Remarks | A | Common Stock | 100000 | $0.00 | 487,081.0000 | 118,998,693 | 25.83% | 0.08% |
| Jan. 15, 2026 | Adawi Kamal | Chief Financial Officer | A | Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 118,998,693 | 9999.99% | 0.06% |
| Jan. 15, 2026 | Valamehr Bahram | President and CEO | A | Common Stock | 335000 | $0.00 | 664,708.0000 | 118,998,693 | 101.61% | 0.28% |
| Jan. 15, 2026 | Valamehr Bahram | President and CEO | A | Stock Option (Right to Buy) | 1300000 | $0.00 | 1,300,000.0000 | 118,998,693 | 9999.99% | 1.09% |
| Jan. 9, 2026 | Valamehr Bahram | President and CEO | S | Common Stock | 5190 | $1.07 | 329,708.0000 | 118,998,693 | 1.55% | 0.00% |
| Jan. 9, 2026 | TAHL CINDY | See Remarks | S | Common Stock | 10589 | $1.06 | 387,081.0000 | 118,998,693 | 2.66% | 0.01% |
| Oct. 20, 2025 | Adawi Kamal | Chief Financial Officer | A | Common Stock | 75000 | $0.00 | 75,000.0000 | 118,998,693 | 9999.99% | 0.06% |
| Oct. 20, 2025 | Adawi Kamal | Chief Financial Officer | A | Stock Option (Right to Buy) | 375000 | $0.00 | 375,000.0000 | 118,998,693 | 9999.99% | 0.32% |
| Aug. 4, 2025 | TAHL CINDY | See Remarks | S | Common Stock | 9037 | $1.06 | 397,670.0000 | 113,685,177 | 2.22% | 0.01% |
| Aug. 4, 2025 | Valamehr Bahram | President and CEO | S | Common Stock | 14466 | $1.06 | 334,898.0000 | 113,685,177 | 4.14% | 0.01% |
| May 29, 2025 | Mozaffarian Neelufar | Not found | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 113,685,177 | 9999.99% | 0.05% |
| May 29, 2025 | EPSTEIN ROBERT S | Not found | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 113,685,177 | 9999.99% | 0.05% |
| May 29, 2025 | ABERNETHY MATT | Not found | A | Stock Option (Right to Buy) | 110000 | $0.00 | 110,000.0000 | 113,685,177 | 9999.99% | 0.10% |
| May 29, 2025 | Agarwal Shefali | Not found | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 113,685,177 | 9999.99% | 0.05% |
| May 29, 2025 | Lee Michael Stewart | Director | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 113,685,177 | 9999.99% | 0.05% |
| May 29, 2025 | Redmile Group, LLC | Director | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 113,685,177 | 9999.99% | 0.05% |
| May 29, 2025 | Xu Yuan | Not found | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 113,685,177 | 9999.99% | 0.05% |
| May 29, 2025 | RASTETTER WILLIAM H | Not found | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 113,685,177 | 9999.99% | 0.05% |
| May 29, 2025 | MENDLEIN JOHN | Not found | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 113,685,177 | 9999.99% | 0.05% |
| May 29, 2025 | Jooss Karin | Not found | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 113,685,177 | 9999.99% | 0.05% |
| Jan. 15, 2025 | Bressi Jerome Charles | See Remarks | A | Stock Option (Right to Buy) | 250000 | $0.00 | 250,000.0000 | 113,685,177 | 9999.99% | 0.22% |
| Jan. 15, 2025 | TAHL CINDY | See Remarks | A | Common Stock | 70000 | $0.00 | 406,707.0000 | 113,685,177 | 20.79% | 0.06% |
| Jan. 16, 2025 | Valamehr Bahram | President and CEO | A | Stock Option (Right to Buy) | 1300000 | $0.00 | 1,300,000.0000 | 113,685,177 | 9999.99% | 1.14% |
| Jan. 15, 2025 | Bressi Jerome Charles | See Remarks | A | Common Stock | 65000 | $0.00 | 335,203.0000 | 113,685,177 | 24.06% | 0.06% |
| Jan. 15, 2025 | TAHL CINDY | See Remarks | A | Stock Option (Right to Buy) | 275000 | $0.00 | 275,000.0000 | 113,685,177 | 9999.99% | 0.24% |
| Jan. 10, 2025 | Valamehr Bahram | President and CEO | S | Common Stock | 8705 | $1.54 | 349,364.0000 | 113,685,177 | 2.43% | 0.01% |
| Jan. 10, 2025 | TAHL CINDY | See Remarks | S | Common Stock | 5654 | $1.55 | 336,707.0000 | 113,685,177 | 1.65% | 0.00% |
| Jan. 10, 2025 | Bressi Jerome Charles | See Remarks | S | Common Stock | 5980 | $1.55 | 270,203.0000 | 113,685,177 | 2.17% | 0.01% |
| Dec. 20, 2024 | Redmile Group, LLC | Director | S | Common Stock | 341633 | $1.68 | 12,486,313.0000 | 117,769,161 | 2.66% | 0.29% |
| Dec. 20, 2024 | Redmile Group, LLC | Director | P | Common Stock | 397964 | $1.68 | 12,884,277.0000 | 117,769,161 | 3.19% | 0.34% |
| Dec. 20, 2024 | Redmile Group, LLC | Director | J | Class A Convertible Preferred Stock | 116261 | $8.40 | 2,638,825.0000 | 117,769,161 | 4.22% | 0.10% |
| Dec. 20, 2024 | Redmile Group, LLC | Director | J | Class A Convertible Preferred Stock | 116261 | $8.40 | 2,755,086.0000 | 117,769,161 | 4.41% | 0.10% |
| Dec. 20, 2024 | Redmile Group, LLC | Director | J | Cash-settled Swaps | 56331 | $1.68 | 502,769.0000 | 117,769,161 | 10.08% | 0.05% |
| Dec. 20, 2024 | Redmile Group, LLC | Director | J | Common Stock | 1084936 | $1.68 | 11,743,010.0000 | 117,769,161 | 8.46% | 0.92% |
| Dec. 20, 2024 | Redmile Group, LLC | Director | J | Common Stock | 1084936 | $1.68 | 12,827,946.0000 | 117,769,161 | 9.24% | 0.92% |
| Dec. 12, 2024 | Redmile Group, LLC | Director | C | Class A Convertible Preferred Stock | 6022 | $0.00 | 2,755,086.0000 | 117,769,161 | 0.22% | 0.01% |
| Dec. 12, 2024 | Redmile Group, LLC | Director | C | Common Stock | 30110 | $0.00 | 12,827,946.0000 | 117,769,161 | 0.24% | 0.03% |
| Aug. 6, 2024 | Xu Yuan | Not found | S | Common Stock | 633 | $4.23 | 8,669.0000 | 98,411,162 | 6.80% | 0.00% |
| July 29, 2024 | Valamehr Bahram | Chief R&D Officer | A | Common Stock | 200000 | $0.00 | 358,069.0000 | 98,411,162 | 126.53% | 0.20% |
| July 29, 2024 | TAHL CINDY | General Counsel and Secretary | A | Common Stock | 200000 | $0.00 | 342,361.0000 | 98,411,162 | 140.49% | 0.20% |
| July 29, 2024 | Mozaffarian Neelufar | Not found | A | Stock Option (Right to Buy) | 80000 | $0.00 | 80,000.0000 | 98,411,162 | 9999.99% | 0.08% |
| June 7, 2024 | MENDLEIN JOHN | Not found | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 98,411,162 | 9999.99% | 0.04% |
| June 7, 2024 | Lee Michael Stewart | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 98,411,162 | 9999.99% | 0.04% |
| June 7, 2024 | Redmile Group, LLC | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 98,411,162 | 9999.99% | 0.04% |
| June 7, 2024 | RASTETTER WILLIAM H | Not found | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 98,411,162 | 9999.99% | 0.04% |
| June 7, 2024 | Jooss Karin | Not found | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 98,411,162 | 9999.99% | 0.04% |
| June 7, 2024 | COUGHLIN TIMOTHY | Not found | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 98,411,162 | 9999.99% | 0.04% |
| June 7, 2024 | Agarwal Shefali | Not found | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 98,411,162 | 9999.99% | 0.04% |
| June 7, 2024 | Xu Yuan | Not found | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 98,411,162 | 9999.99% | 0.04% |
| June 7, 2024 | EPSTEIN ROBERT S | Not found | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 98,411,162 | 9999.99% | 0.04% |
| March 21, 2024 | Redmile Group, LLC | Director | A | Pre-Funded Warrants to Purchase Common Stock | 3636364 | $5.50 | 3,893,674.0000 | 98,411,162 | 1413.22% | 3.70% |
| March 4, 2024 | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 2447 | $7.77 | 101,479.0000 | 98,411,162 | 2.35% | 0.00% |
| Feb. 1, 2024 | Dulac Edward J III | Chief Financial Officer | A | Stock Option (Right to Buy) | 425000 | $0.00 | 425,000.0000 | 98,411,162 | 9999.99% | 0.43% |
| Feb. 1, 2024 | Valamehr Bahram | Chief R&D Officer | A | Stock Option (Right to Buy) | 450000 | $0.00 | 450,000.0000 | 98,411,162 | 9999.99% | 0.46% |
| Feb. 1, 2024 | TAHL CINDY | General Counsel and Secretary | A | Stock Option (Right to Buy) | 425000 | $0.00 | 425,000.0000 | 98,411,162 | 9999.99% | 0.43% |
| Feb. 1, 2024 | Wolchko J Scott | President and CEO | A | Stock Option (Right to Buy) | 500000 | $0.00 | 500,000.0000 | 98,411,162 | 9999.99% | 0.51% |
| Jan. 29, 2024 | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 1849 | $5.00 | 103,926.0000 | 98,411,162 | 1.75% | 0.00% |
| Jan. 9, 2024 | TAHL CINDY | General Counsel and Secretary | S | Common Stock | 10874 | $4.37 | 142,361.0000 | 98,411,162 | 7.10% | 0.01% |
| Jan. 9, 2024 | Wolchko J Scott | President and CEO | S | Common Stock | 14391 | $4.37 | 371,248.0000 | 98,411,162 | 3.73% | 0.01% |
| Jan. 9, 2024 | Valamehr Bahram | Chief R&D Officer | S | Common Stock | 11271 | $4.38 | 158,069.0000 | 98,411,162 | 6.66% | 0.01% |
| Jan. 9, 2024 | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 7028 | $4.37 | 105,775.0000 | 98,411,162 | 6.23% | 0.01% |
| Jan. 2, 2024 | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 5182 | $3.66 | 112,803.0000 | 98,411,162 | 4.39% | 0.01% |
| Dec. 26, 2023 | Redmile Group, LLC | Director | P | Common Stock | 44630 | $3.72 | 13,180,388.0000 | 0 | 0.34% | 0.00% |
| Dec. 26, 2023 | Redmile Group, LLC | Director | J | Common Stock | 1655370 | $3.72 | 13,135,758.0000 | 0 | 14.42% | 0.00% |
| Dec. 26, 2023 | Redmile Group, LLC | Director | J | Common Stock | 1655370 | $3.72 | 13,135,758.0000 | 0 | 11.19% | 0.00% |
| Dec. 18, 2023 | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 1585 | $3.50 | 117,985.0000 | 0 | 1.33% | 0.00% |
| Nov. 9, 2023 | TAHL CINDY | General Counsel and Secretary | S | Common Stock | 24363 | $2.40 | 153,235.0000 | 0 | 13.72% | 0.00% |
| Aug. 18, 2023 | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 4718 | $2.80 | 119,570.0000 | 0 | 3.80% | 0.00% |
| Aug. 4, 2023 | Xu Yuan | Director | S | Common Stock | 632 | $3.71 | 9,302.0000 | 0 | 6.36% | 0.00% |
| July 5, 2023 | Powl Brian T. | Chief Commercial Officer | S | Common Stock | 3854 | $4.87 | 41,146.0000 | 0 | 8.56% | 0.00% |
| July 5, 2023 | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 5182 | $4.83 | 124,288.0000 | 0 | 4.00% | 0.00% |
| June 14, 2023 | Xu Yuan | Director | S | Common Stock | 3460 | $5.58 | 9,934.0000 | 0 | 25.83% | 0.00% |
| June 6, 2023 | Redmile Group, LLC | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2023 | Lee Michael Stewart | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2023 | Xu Yuan | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2023 | RASTETTER WILLIAM H | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2023 | MENDLEIN JOHN | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2023 | Jooss Karin | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2023 | HERSHBERG ROBERT | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2023 | EPSTEIN ROBERT S | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2023 | COUGHLIN TIMOTHY | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2023 | Agarwal Shefali | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| April 20, 2023 | Redmile Group, LLC | Director | P | Common Stock | 20000 | $5.99 | 12,879,119.0000 | 0 | 0.16% | 0.00% |
| April 21, 2023 | Redmile Group, LLC | Director | P | Common Stock | 256639 | $6.18 | 13,135,758.0000 | 0 | 1.99% | 0.00% |
| April 18, 2023 | Chu Yu-Waye | Chief Medical Officer | S | Common Stock | 215 | $6.52 | 142,993.0000 | 0 | 0.15% | 0.00% |
| April 18, 2023 | Chu Yu-Waye | Chief Medical Officer | S | Common Stock | 2317 | $6.58 | 140,676.0000 | 0 | 1.62% | 0.00% |
| April 14, 2023 | Redmile Group, LLC | Director | J | Pre-Funded Warrants to Purchase Common Stock | 54960 | $5.84 | 257,310.0000 | 0 | 17.60% | 0.00% |
| April 14, 2023 | Redmile Group, LLC | Director | J | Pre-Funded Warrants to Purchase Common Stock | 54960 | $5.84 | 257,310.0000 | 0 | 27.16% | 0.00% |
| April 14, 2023 | Redmile Group, LLC | Director | J | Cash-settled Swaps | 550000 | $5.84 | 559,100.0000 | 0 | 49.59% | 0.00% |
| April 14, 2023 | Redmile Group, LLC | Director | J | Cash-settled Swaps | 550000 | $5.84 | 559,100.0000 | 0 | 6043.96% | 0.00% |
| April 14, 2023 | Redmile Group, LLC | Director | P | Common Stock | 25700 | $6.00 | 12,859,119.0000 | 0 | 0.20% | 0.00% |
| April 13, 2023 | Redmile Group, LLC | Director | C | Class A Convertible Preferred Stock | 33441 | $0.00 | 2,761,108.0000 | 0 | 1.20% | 0.00% |
| April 14, 2023 | Redmile Group, LLC | Director | J | Class A Convertible Preferred Stock | 45752 | $29.20 | 2,761,108.0000 | 0 | 1.63% | 0.00% |
| April 14, 2023 | Redmile Group, LLC | Director | J | Class A Convertible Preferred Stock | 45752 | $29.20 | 2,761,108.0000 | 0 | 1.68% | 0.00% |
| April 14, 2023 | Redmile Group, LLC | Director | J | Common Stock | 5492385 | $5.84 | 12,833,419.0000 | 0 | 74.82% | 0.00% |
| April 14, 2023 | Redmile Group, LLC | Director | J | Common Stock | 5492385 | $5.84 | 12,833,419.0000 | 0 | 29.97% | 0.00% |
| April 14, 2023 | Redmile Group, LLC | Director | S | Common Stock | 302339 | $5.84 | 12,833,419.0000 | 0 | 2.30% | 0.00% |
| April 13, 2023 | Redmile Group, LLC | Director | C | Common Stock | 167205 | $0.00 | 13,135,758.0000 | 0 | 1.29% | 0.00% |
| Feb. 6, 2023 | Wolchko J Scott | President and CEO | A | Stock Option (Right to Buy) | 500000 | $0.00 | 500,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 6, 2023 | Valamehr Bahram | Chief R&D Officer | A | Stock Option (Right to Buy) | 450000 | $0.00 | 450,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 6, 2023 | Powl Brian T. | Chief Commercial Officer | A | Stock Option (Right to Buy) | 425000 | $0.00 | 425,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 6, 2023 | TAHL CINDY | General Counsel and Secretary | A | Stock Option (Right to Buy) | 425000 | $0.00 | 425,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 6, 2023 | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 425000 | $0.00 | 425,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 6, 2023 | Dulac Edward J III | Chief Financial Officer | A | Stock Option (Right to Buy) | 425000 | $0.00 | 425,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 19, 2023 | MENDLEIN JOHN | Director | M | Stock Option (Right to Buy) | 28461 | $0.00 | 0.0000 | 0 | 0.00% | 0.00% |
| Jan. 19, 2023 | MENDLEIN JOHN | Director | M | Common Stock | 28461 | $1.37 | 311,231.0000 | 0 | 10.07% | 0.00% |
| Jan. 11, 2023 | MENDLEIN JOHN | Director | P | Common Stock | 88048 | $5.67 | 246,139.0000 | 0 | 55.69% | 0.00% |
| Jan. 13, 2023 | MENDLEIN JOHN | Director | P | Common Stock | 36631 | $5.43 | 282,770.0000 | 0 | 14.88% | 0.00% |
| Jan. 12, 2023 | Valamehr Bahram | Chief R&D Officer | M | Common Stock | 423 | $1.37 | 169,340.0000 | 0 | 0.25% | 0.00% |
| Jan. 12, 2023 | Valamehr Bahram | Chief R&D Officer | M | Stock Option (Right to Buy) | 423 | $0.00 | 0.0000 | 0 | 0.00% | 0.00% |
| Jan. 10, 2023 | Chu Yu-Waye | Chief Medical Officer | S | Common Stock | 7825 | $5.24 | 143,208.0000 | 0 | 5.18% | 0.00% |
| Jan. 10, 2023 | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 7331 | $5.24 | 129,470.0000 | 0 | 5.36% | 0.00% |
| Jan. 10, 2023 | Plavsic Mark | Chief Technical Officer | S | Common Stock | 3418 | $5.24 | 123,705.0000 | 0 | 2.69% | 0.00% |
| Jan. 10, 2023 | TAHL CINDY | General Counsel and Secretary | S | Common Stock | 11553 | $5.24 | 177,598.0000 | 0 | 6.11% | 0.00% |
| Jan. 10, 2023 | Valamehr Bahram | Chief R&D Officer | S | Common Stock | 10917 | $5.24 | 168,917.0000 | 0 | 6.07% | 0.00% |
| Jan. 10, 2023 | Wolchko J Scott | President and CEO | S | Common Stock | 45907 | $5.24 | 385,639.0000 | 0 | 10.64% | 0.00% |